Side-by-side · Research reference

Kisspeptin-10vsSS-31

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/41 cited

BPhase 3HUMAN-REVIEWED9/43 cited

Kisspeptin-10

Neuropeptide · GPR54 Agonist

GnRH pulse generatorPrimary roleSilva 2026

Phase 1/2Clinical stage

GPR54/Kiss1RTarget receptorRønnekleiv 2026

IV / SQ · Investigational

SS-31

Cardiolipin-binding · Mitochondrial protective

40 mgDaily doseSzeto 2014

Phase 3Evidence levelSzilagyi 2009 Szeto 2014

~3 hrHalf-life

SQ · Abdomen · Once daily

01Mechanism of Action

Parameter

Kisspeptin-10

SS-31

Primary target

GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026 Collado-Sole 2026

Cardiolipin in inner mitochondrial membraneSzeto 2014

Pathway

Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026 Rønnekleiv 2026

Cardiolipin binding → cristae stabilisation → ETC integrity → reduced ROS + preserved ATP synthesisSzeto 2014 Szilagyi 2009

Downstream effect

Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026

Mitochondrial bioenergetic preservation; cardio-, neuro-, and reno-protective effects in animal + clinical studiesSzeto 2014

Feedback intact?

Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026 Rønnekleiv 2026

—

Origin

C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms

Synthetic tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂; cell-permeable, mitochondrial-selectiveSzeto 2014

Antibody development

—

02Dosage Protocols

Parameter

Kisspeptin-10

SS-31

Clinical trial dose

Phase 1/2 investigational

Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).

—

Route

IV or SQ administration

IV preferred in controlled trials for precise pulsatile delivery.

—

Evidence basis

Phase 1/2 trials

Multiple Phase 3 trials (Barth, AMD, ischemia-reperfusion)Szeto 2014 Szilagyi 2009

Half-life

Short (minutes)

Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.

~3 h plasma; tissue uptake longer

Standard dose

—

40 mg / day SQ (clinical trials)Szeto 2014

Anecdotal community range 5-10 mg/day. Phase 3 trials use 40 mg.

Frequency

—

Once daily

Lower / starter dose

—

5 mg / day (anecdotal)

Duration

—

Indefinite for mitochondrial disease; cycled for healthspan use

Reconstitution

—

Bacteriostatic water

Timing

—

Morning fasted preferred; pre-workout for exercise-induced mitochondrial stress

04Side Effects & Safety

Parameter

Kisspeptin-10

SS-31

Ovarian hyperstimulation

Theoretical risk with supraphysiological dosing in fertility protocols

—

Headache

Mild, reported in early-phase trials

Reported in some Phase 3 trials

Nausea

Transient GI symptoms with IV bolus

—

Hot flashes

Vasomotor symptoms from LH surge

—

Injection site reaction

Erythema, mild discomfort (SQ route)

Erythema, mild pruritus

GI symptoms

—

Nausea (uncommon)

Cardiovascular

—

Cardio-protective in studies; no signal of harm

Long-term safety

—

Phase 3 data over 24+ months; no major safety signalsSzeto 2014

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

Kisspeptin-10

·Active pregnancy
·Hormone-sensitive malignancy (breast, ovarian, endometrial)

SS-31

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

Kisspeptin-10

·Polycystic ovary syndrome (PCOS) without monitoring
·Uncontrolled thyroid dysfunction

SS-31

·None established

05Administration Protocol

Parameter

Kisspeptin-10

SS-31

1. Reconstitution (if lyophilized)

Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.

Add bacteriostatic water per label. Light-protected handling.

2. Route selection

IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.

SQ — abdomen or thigh. Rotate sites.

3. Timing

Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.

Morning fasted; pre-workout for exercise-augmented mitochondrial stress.

4. Monitoring

Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

5. Storage

Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Kisspeptin-10

— no documented stacks

SS-31

+ MOTS-c

Moderate

View MOTS-c →

SS-31 and MOTS-c address mitochondrial decline through complementary axes. SS-31 protects existing mitochondrial structure (cardiolipin binding, cristae stabilisation). MOTS-c upregulates AMPK/PGC-1α, triggering biogenesis of new mitochondria. Together they pair preservation with renewal — anecdotally favoured in healthspan and post-cardio-event recovery protocols.

SS-31: 5–10 mg SQ · daily morning
MOTS-c: 5 mg SQ · 2× per week pre-workout
Primary benefit: Mitochondrial preservation + biogenesis